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abstract
PURPOSE PROSTVAC, a viral vector–based immunotherapy, prolonged median overall survival (OS) by
8.5 months versus placebo in metastatic castration-resistant prostate cancer in a phase II study. This phase III
study further investigated those findings.
PATIENTS AND METHODS Patients were randomly assigned to PROSTVAC (Arm V; n = 432), PROSTVAC plus
granulocyte-macrophage colony-stimulating factor (Arm VG; n = 432), or placebo (Arm P; n = 433), stratified by
prostate-specific antigen (less than 50 ng/mL v 50 ng/mL or more) and lactate dehydrogenase (less than 200 v
200 U/L or more). Primary end point was OS. Secondary end points were patients alive without events
(AWE)—namely, radiographic progression, pain progression, chemotherapy initiation, or death—at 6 months
and safety. The study design was a superiority trial of PROSTVAC (Arm V or Arm VG) versus Arm P. Three interim
analyses were planned.
RESULTS At the third interim analysis, criteria for futility were met and the trial was stopped early. Neither active
treatment had an effect on median OS (Arm V, 34.4 months; hazard ratio, 1.01; 95% CI, 0.84 to 1.20; P = .47;
Arm VG, 33.2 months; hazard ratio, 1.02; 95% CI, 0.86 to 1.22; P = .59; Arm P, 34.3 months). Likewise, AWE at
6 months was similar (Arm V, 29.4%; odds ratio, 0.96; 95% CI, 0.71 to 1.29; Arm VG, 28.0%; odds ratio, 0.89;
95% CI, 0.66 to 1.20; placebo, 30.3%). Adverse events were similar for the treatment and placebo groups, with
the most common being injection site reactions (62% to 72%) and fatigue (21% to 24%). Arrhythmias were the
most common cardiac-related events (1.4% to 3.5%). There were no reports of either myocarditis or pericarditis.
Serious treatment-related events occurred in less than 1% of all patients.
CONCLUSION Whereas PROSTVAC was safe and well tolerated, it had no effect on OS or AWE in metastatic
castration-resistant prostate cancer. Combination therapy is currently being explored in clinical trials.
J Clin Oncol 37:1051-1061. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
The treatment algorithm for metastatic castration-
resistant prostate cancer (mCRPC) continues to evolve
as research brings new survival-prolonging therapies
to the clinic. The mainstay of treatment for mCRPC is
androgen-deprivation therapy through pharmacologic
and surgical strategies.1,2 During the last decade,
second-generation antiandrogen agents—abiraterone
and enzalutamide—have received US Food and Drug
Administration approval for mCRPC.3-6 Other treat-
ment modalities for mCRPC that have demonstrated
overall survival (OS) benefits include chemother-
apy (docetaxel and cabazitaxel),7-9 immunotherapy
(sipuleucel-T),10 and targeted a-therapy (radium-223).11
PROSTVAC is an active immunotherapy vaccine that
contains prostate-specific antigen (PSA) as the tumor-
associated antigen used to generate a T-cell response
against prostate cancer. PROSTVAC is composed of a
heterologous prime-boost regimen using two different
live poxviral-based vectors: PROSTVAC-V, a recombi-
nant vaccinia virus (rilimogene galvacirepvec), and
PROSTVAC-F, a recombinant fowlpox virus (rilimogene
glafolivec). Both vectors contain transgenes for human
PSA and three costimulatory molecules for T cells—
collectively referred to as TRICOM: B7.1, leukocyte
function-associated antigen-3, and intercellular adhe-
sion molecule-1—to enhance immune activation.12 On
the basis of the hypothesis of potential enhancement of
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T-cell responses, PROSTVAC has been evaluated in clinical
trials in combination with granulocyte-macrophage colony-
stimulating factor (GM-CSF),13,14 a cytokine with immuno-
modulatory activity15; however, the necessity of GM-CSF was
not established definitively in these earlier studies.
Results from a randomized, double-blind, phase II trial
generated the hypothesis that PROSTVAC might prolong
OS, although it did not prolong progression-free survival,
the study’s primary end point, or produce any objective
tumor responses.14,16 To validate this hypothesis and
confirm the role of GM-CSF as an adjuvant, we designed a
phase III trial, the results of which are reported here.
PATIENTS AND METHODS
Patients
Eligibility criteria included men age 18 years or older with
documented asymptomatic or minimally symptomatic ev-
idence of mCRPC and documented progressive disease
(either radiologic or by PSA progression), castrate testos-
terone level less than 50 ng/dL, current use of a gonadotropin-
releasing hormone agonist or antagonist (unless surgically
castrated), and chemotherapy naı¨ve for metastatic prostate
cancer (neoadjuvant or adjuvant chemotherapy for primary
prostate cancer was permitted if completed more than
3 years before screening). A 6-week washout period was
required for patients on antiandrogen therapy—4 weeks if
on flutamide. Concomitant medications to prevent bone
loss or skeletal-related events, including bisphosphonates
and denosumab, as well as palliative radiotherapy were
permitted during the trial.
Exclusion criteria included cancer-related pain that re-
quired scheduled opioid narcotics—as needed two times
per week or fewer was permitted—and current or prior use
of sipuleucel-T for prostate cancer.
Study Design
This was a phase III, international, multicenter, random-
ized, double-blind, placebo-controlled study. Patients were
stratified by PSA (less than 50 ng/mL v 50 ng/mL or more)
and lactate dehydrogenase (less than 200 U/L v 200 U/L or
more) at screening and block randomly assigned 1:1:1 to
PROSTVAC plus GM-CSF (Arm VG), PROSTVAC plus
placebo GM-CSF (Arm V), or vaccine placebo plus placebo
GM-CSF (Arm P) using an interactive voice response
system from a randomization list generated by a third-party
vendor. GM-CSF (sargramostim; Leukine [Sanofi, Bridge-
water, NJ]; 250 mg, lyophilized), a glycosylated, recombi-
nant human GM-CSF, was manufactured by Genzyme.
GM-CSF placebo was USP grade or equivalent bacterio-
static sodium chloride (saline) for injection. GM-CSF was
added as adjuvant therapy to one treatment arm to explore
whether this immune modulator enhanced the activity of
PROSTVAC, as data on its potential benefit in cancer
therapy are inconsistent.13,17-19 An empty vector fowlpox
was used for the placebo vaccination as it is nonreplicating
in humans; has minimal safety risks, including no known
effects on cancer progression; and an adverse effect
profile, including injection site reactions, that is over-
lapping and generally indistinguishable from sub-
cutaneously administered vaccinia. This trial is registered
with the European Clinical Trial Database (EudraCT 2010-
021196-85).
The study consisted of three periods: screening, treatment,
and long-term follow-up (LTFU). During the treatment
phase, a total of seven vaccinations were subcutaneously
administered—a single priming immunization of PROST-
VAC-V or placebo in week 1 followed by six boosting im-
munizations with PROSTVAC-F or placebo administered in
weeks 3, 5, 9, 13, 17, and 21. Subcutaneous GM-CSF or
placebo was administered—within 5 mm of the original
injection site—on the day of immunization and for 3
consecutive days thereafter beginning with week 1, for a
total of 28 doses. After the end-of-treatment visit—week 25/
early termination—all patients were automatically entered
into the LTFU phase, with study visits occurring every
6 months. During the treatment phase (approximately
5 months), chemotherapy, immunotherapy (eg, sipuleucel-T)
or immunosuppressive therapy (eg, etanercept or natali-
zumab), systemic corticosteroids (daily or continued use
every other day for more than 14 days), anticancer ra-
dionuclides, and secondary anticancer hormonal treat-
ments (eg, abiraterone) were prohibited. During LTFU,
patients received standard-of-care treatment as deter-
mined by the investigator.
The study was approved by local or central institutional
review boards or ethics committees for each participating
site and conducted according to the provisions of the
Declaration of Helsinki and Good Clinical Practice Guide-
lines of the International Conference on Harmonization. All
patients provided written informed consent before any
screening procedures were initiated.
Outcomes
Primary end point of the study was OS, defined as the time
between the date of random assignment and the date of
death as a result of any cause. Secondary end point was the
proportion of patients alive without events (AWE)—namely,
radiographic progression, pain progression, initiation of
chemotherapy for prostate cancer, or death—at 6 months
post–random assignment. Safety end points included ad-
verse events, vital signs, and 12-lead ECG. Adverse events
were graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events (version
4.0). Tumor response was according to Response Evalu-
ation Criteria in Solid Tumors (RECIST) criteria 1.1.
Exploratory/other end points included survival on the basis
of HLA-A2 status, postvaccination cancer treatments
(abiraterone acetate, enzalutamide, or sipuleucel-T), and
growth rate constant calculated using PSA values from
screening through week 25/end-of-treatment visit.
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Statistical Analysis
All efficacy analyses were conducted using the intention-
to-treat population, defined as all randomly assigned
patients, with analysis according to the randomized
treatment arm. Safety analyses were conducted using the
full analysis set population, defined as all patients who
initiated treatment. Primary analysis was based on a
stratified log-rank test. Hazard ratio was estimated using
stratified Cox proportional hazards regression analysis,
with ties handled by the exact method. Survival data were
plotted using the Kaplan-Meier method. An estimated
534 deaths in a between-arm comparison was needed to
achieve a target hazard ratio of 0.68 with a one-sided type
I error of 0.0125 and a target power of 85% or greater. The
number of patients per arm was set at 400 for an ap-
proximate total of 1,200 patients.
Two main overall comparisons of the primary end point
were planned—one between Arm V and Arm P and the
other between Arm VG and Arm P—and these were per-
formed using a Bonferroni correction for the overall type I
error probability such that the probability for each one-
sided comparison would not exceed 0.0125 (0.025/2). Trial
success was defined as meeting the statistical criterion for
either comparison. The same comparisons performed for
survival were performed for AWE using the same signifi-
cance levels. AWE end point was analyzed using a logistic
regression model stratified by randomization strata. The
95% CI for the odds ratio (OR) estimate was computed as
the measure of effect size.
Three interim analyses were planned for OS superiority and
futility after 321, 481, and 641 deaths, which represented
40%, 60%, and 80% of the deaths required for final
analysis (801 deaths in the three arms). In addition to the
O’Brien-Fleming efficacy stopping boundaries to control
the overall type I error, a significance level of 0.00001 was
used for detection of futility at each interim analysis. An
unblinded independent third-party vendor performed in-
terim analyses. Results were assessed by an independent
data monitoring committee. SAS (SAS/STAT User’s Guide,
Version 9.2; SAS Institute, Cary, NC) was used for all
statistical analyses.
RESULTS
Patient Characteristics and Disposition
A total of 1,749 patients from 105 sites in 16 countries were
screened, and 1,297 were randomly assigned to one of the
three treatment arms, comprising the intention-to-treat
population. Of these, 11 patients were never treated;
therefore, the full analysis set/safety population consisted
of 1,286 patients. The first patient was screened in No-
vember 2011 and the last patient completed the treatment
phase in July 2015. After the third interim analysis, criteria
for futility were met and, on the recommendation of the
DMC, the trial was stopped early (September 25, 2017) and
the date of last follow-up was October 02, 2017. A flowchart
of patient enrollment and disposition is shown in Figure 1.
A similar proportion of treated patients in all arms (65% to
70%) completed the treatment period. Reasons for dis-
continuation were also similar among the study arms,
with progressive disease (23.4%; 301 of 1,286 patients)
being the most common, whereas adverse events
accounted for 3.5% (45 of 1,286 patients) of all treatment
discontinuations.
The majority of treated patients in each arm (94% to 96%)
entered the LTFU phase (Fig 1). As follow-up was to
continue until death as a result of any cause, death was
the most common reason for discontinuation from LTFU.
Given the DMC recommendation to stop the trial early, the
second most common reason was study termination by
sponsor.
Patients were evenly distributed across the treatment
arms by demographic and disease characteristics
(Table 1). Mean age of the study population was 71 years
(range, 45 to 93 years), and the primary site of metastasis
in all study arms was bone, occurring in approximately
75% of patients. Approximately one third of all patients
reported a history of cardiac disorders, with coronary
artery disorders being the most common at approximately
20%.
Primary End Point
As shown in the Kaplan-Meier curves (Fig 2), the two
active arms were not different from placebo with respect to
OS. Median OS was 34.4 months in Arm V, 33.2 months in
Arm VG, and 34.3 months in Arm P. The hazard ratio for
comparison with placebo was 1.01 (95% CI, 0.84 to 1.20;
P = .47) for Arm V and 1.02 (95%CI, 0.86 to 1.22; P = .59)
for Arm VG.
Secondary End Point
Likewise, the proportion of patients AWE at 6 months post-
randomization was similar across treatment arms (Arm V;
29.4%; OR, 0.96; 95%CI, 0.71 to 1.29; Arm VG: 28.0%; OR,
0.89; 95%CI, 0.66 to 1.20; ArmP: 30.3%; Table 2). Themost
common event was radiographic progression, which occurred
in approximately 60% of patients, followed by pain progres-
sion, which ranged from 6.5% in Arm V to 10.4% in Arm P.
Exploratory/Other End Points
HLA-A2 status—positive versus negative—did not influ-
ence OS (Table 3). Whereas there were significant differ-
ences in OS between postvaccination cancer therapy—yes
versus no—and between tumor growth rate quartiles, there
were no differences between treatments within each
subgroup (Table 3, Data Supplement Figures A2, A3).
Tumor response results were similar across treatments
(Table 4, Data Supplement Figure A1). At week 25/end of
treatment, only one patient achieved a complete response
and this was observed in a placebo-treated patient. A best
Journal of Clinical Oncology 1053
PROSTVAC 6 GM-CSF in Asymptomatic/Minimally Symptomatic mCRPC
Downloaded from ascopubs.org by Radboud University Nijmegen on May 6, 2020 from 131.174.248.182
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
response of partial response was observed in less than 1%
of patients in each study arm.
Safety
Nearly all treated patients—approximately 91%—experienced
at least one treatment-emergent adverse event (TEAE). As
expected, the most common events in all three treatment
arms were injection site reactions, which occurred in 62%
to 72% of patients. The most common noninjection site
event for all treatment arms was fatigue, which occurred in
21% to 24% of patients. Whereas at least one grade 3 or
greater TEAE was reported in 21% to 23% of patients, the
majority (more than 75%) of all TEAEs were mild in severity
(grade 1). Adverse events that led to treatment discon-
tinuation occurred in 4.9% (21 of 429 patients), 6.5% (28
of 429 patients), and 5.8% (25 of 428 patients) of patients
in Arm V, Arm VG, and Arm P, respectively. In only a
minority of patients were the events considered treatment
related (Arm V: 0.9% [four of 429 patients]; Arm VG: 3.0%
[13 of 429 patients]; Arm P: 1.6% [seven of 428 patients]).
The most common TEAEs that led to treatment discon-
tinuation in the study arms were bone pain (n = 6; two
patients in each treatment arm) and spinal cord com-
pression (n = 6; one patient in each PROSTVAC arm and
four patients in the placebo arm). A total of nine patients
(Arm V, n = 3; Arm VG, n = 4; Arm P, n = 2) experienced 10
serious adverse events that were considered by study in-
vestigators to be treatment related, but no single event
occurred in more than one patient each per study arm. The
most common treatment-related TEAEs by toxicity grade
are shown in Table 5. Overall, treatment-related adverse
events were more commonly observed in Arm VG (79.3%)
Screened
(N = 1,749)
Randomly assigned
(n = 1,297)
Screen failures
   Eligibility criteria not met
   Consent withdrawn
   Other
(n = 452)
(n = 367)
(n = 62)
(n = 23)
Arm V
(n = 432; ITT)
Treated
Not treated
 (n = 429; FAS)
              (n = 3)
Arm V treated
(n = 429)
Completed
Discontinued
   Progressive disease
   Consent withdrawn
   Adverse event
   Protocol violation
   Death
   Other
(n = 300)
(n = 129)
(n = 89)
(n = 14)
(n = 12)
(n = 7)
(n = 5)
(n = 2)
Arm V, LTFU
(n = 409)
Reasons for withdrawal
   Death
   Study termination
   Consent withdrawn
   Lost to follow-up
   Other
(n = 235)
(n = 160)
(n = 9)
(n = 2)
(n = 3)
Arm VG
(n = 432; ITT)
Treated
Not treated
   (n = 429; FAS)
               (n = 3)
Completed
Discontinued
   Progressive disease
   Consent withdrawn
   Adverse event
   Protocol violation
   Death
   Other
(n = 279)
(n = 150)
(n = 100)
(n = 16)
(n = 18)
(n = 5)
(n = 7)
(n = 4)
Arm VG treated
(n = 429)
Arm VG, LTFU
(n = 405)
Reasons for withdrawal
   Death
   Study termination
   Consent withdrawn
   Lost to follow-up
   Other
(n = 239)
(n = 158)
(n = 6)
(n = 2)
(n = 3)
Arm P
(n = 433; ITT)
Treated
Not treated
 (n = 428; FAS)
              (n = 5)
Completed
Discontinued
   Progressive disease
   Consent withdrawn
   Adverse event
   Protocol violation
   Death
   Other
(n = 280)
(n = 148)
(n = 112)
(n = 11)
(n = 15)
(n = 4)
(n = 3)
(n = 3)
Arm P treated
(n = 428)
Arm P, LTFU
(n = 413) 
Reasons for withdrawal
   Death
   Study termination
   Consent withdrawn
   Lost to follow-up
   Other
(n = 236)
(n = 165)
(n = 6)
(n = 3)
(n = 3)
FIG 1. Patient disposition. Safety
was assessed using the full analysis
set population (FAS). Arm P, pla-
cebo; Arm V, PROSTVAC; Arm VG,
PROSTVAC+granulocyte-macrophage
colony-stimulating factor; ITT,
intention-to-treat population, LTFU,
long-term follow-up.
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compared with Arm V (72.7%) or placebo (70.6%), and this
was especially noticeable with pyrexia (19.3%, 6.5%, and
11.0%, respectively) and injection site reactions. Cardiac
disorders occurred in less than 5% of all treated patients,
with no differences across treatment arms. Arrhythmias
were the most commonly reported cardiac-related TEAEs,
occurring in 1.4% (Arm VG) to 3.5% (placebo) of all pa-
tients. There were no reports of myocarditis or pericarditis.
TABLE 1. Baseline Demographics and Disease Characteristics
Characteristic Arm V (n = 432) Arm VG (n = 432) Arm P (n = 433)
Mean age, years (SD) 71.3 (8.0) 70.6 (8.4) 71.4 (8.3)
Race, No. (%)
White 404 (93.5) 400 (92.6) 403 (93.1)
African American 17 (3.9) 25 (5.8) 23 (5.3)
Asian 7 (1.6) 6 (1.4) 7 (1.6)
Other or missing 4 (0.9) 1 (0.2) 0
Not Hispanic or Latino, No. (%) 418 (96.8) 421 (97.5) 415 (95.8)
Geographic region, No. (%)
North America 156 (36.1) 155 (35.9) 157 (36.3)
Eastern Europe 63 (14.6) 68 (15.7) 72 (16.6)
Rest of the world 213 (49.3) 209 (48.4) 204 (47.1)
Mean BMI, kg/m2 (SD) 28.5 (4.4) 28.7 (4.8) 28.4 (4.6)
ECOG performance status, No. (%)
0 310 (71.8) 322 (74.5) 330 (76.2)
1 120 (27.8) 107 (24.8) 103 (23.8)
2 1 (0.2) 2 (0.5) 0
Missing 1 (0.2) 1 (0.2) 0
HLA-A2 Status, No. (%)
Positive 200 (46.3) 192 (44.4) 183 (42.3)
Negative 190 (44.0) 185 (42.8) 203 (46.9)
Missing 42 (9.7) 55 (12.7) 47 (10.9)
Mean PSA, ng/mL (SD) 71.4 (167.4) 69.4 (192.1) 82.6 (257.8)
Randomization strata, No. (%)
PSA , 50 ng/mL and LDH , 200 U/L 168 (38.9) 168 (38.9) 168 (38.8)
PSA , 50 ng/mL and LDH $ 200 U/L 135 (31.3) 135 (31.3) 135 (31.2)
PSA $ 50 ng/mL and LDH , 200 U/L 65 (15.0) 64 (14.8) 64 (14.8)
PSA $ 50 ng/mL and LDH $ 200 U/L 64 (14.8) 65 (15.0) 66 (15.2)
Mean hemoglobin, g/L (SD) 130.8 (12.2) 130.5 (12.8) 131.7 (13.7)
Mean ALP, U/L (SD) 94.8 (45.9) 99.9 (49.4) 99.7 (51.8)
Mean years since initial diagnosis (SD) 6.6 (4.7) 6.3 (5.4) 6.0 (5.2)
Primary site of metastasis, No. (%)
Bone 320 (74.1) 323 (74.8) 326 (75.3)
Lymph nodes 62 (14.4) 72 (16.7) 69 (15.9)
Visceral 41 (9.5) 32 (7.4) 36 (8.3)
No metastasis 2 (0.5) 1 (0.2) 0
Baseline pain
Yes 137 (31.7) 142 (32.9) 138 (31.9)
No 228 (52.8) 227 (52.5) 224 (51.7)
Missing 67 (15.5) 63 (14.6) 71 (16.4)
Abbreviations: ALP, alkaline phosphatase; Arm P, placebo; Arm V, PROSTVAC; Arm VG, PROSTVAC + granulocyte-macrophage colony-stimulating factor;
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PSA, prostate-specific antigen; SD, standard deviation.
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DISCUSSION
In this phase III study, PROSTVAC did not meet the primary
OS end point compared with control in patients with
asymptomatic or minimally symptomatic mCRPC. These
results did not support the positive signal from the ran-
domized phase II study.14
A few possibilities may account for these findings: the
phase II finding generated a false-positive signal as a result
of being underpowered for an OS comparison, the relatively
small sample size (82 PROSTVAC-treated v 40 placebo-
treated patients), and/or potential observer bias (long-term
OS data were collected after database lock and study
unblinding).14,16 Moreover, an imbalance in prognostic
factors, both known and unknown, may have negatively
affected the observed median OS in the phase II control
arm (16.6 months). This was lower than expected
compared with the Halabi prognostic nomogram-predicted
OS (PSA, lactate dehydrogenase, alkaline phosphatase,
and hemoglobin; 20.4 months).14,20 Survival in the control
arm relative to expected outcomes may be the origin of the
flawed comparison, which is supported by the OS in the
control arm of the sipuleucel-T pivotal trial (21.7 months).10
Finally, docetaxel was the only life-prolonging treatment
available during our phase II study. From the time the
phase III protocol was finalized (2010) until the last patient
was randomly assigned (January 2015), multiple treat-
ments became available—cabazitaxel,9 sipuleucel-T,10
abiraterone acetate3,4 enzalutamide,5,6 and radium-
22311—and we observed an approximate 3-year median
OS in the placebo group. It should be noted that in similar
predocetaxel patient populations, OS benefit in clearly
clinically active agents—abiraterone and enzalutamide—
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FIG 2. Kaplan-Meier estimates for overall
survival (OS). Arm P, placebo; Arm V,
PROSTVAC; Arm VG, PROSTVAC +
granulocyte-macrophage colony-
stimulating factor; HR, hazard ratio.
TABLE 2. Patients at 6 Months Postrandomization
Variable Arm V (n = 432) Arm VG (n = 432) Arm P (n = 433)
AWE at 6 Months, No. (%) 127 (29.4) 121 (28.0) 131 (30.3)
Difference, % (95% CI) 20.9 (27.0 to 5.2) 22.2 (28.3 to 3.8)
Odds ratio (95% CI) 0.96 (0.71 to 1.29) 0.89 (0.66 to 1.20)
Event at 6 months, No. (%) 305 (70.6) 311 (72.0) 302 (69.7)
Radiographic progression 273 (63.2) 265 (61.3) 258 (59.6)
Pain progression 28 (6.5) 40 (9.3) 45 (10.4)
Initiation of chemotherapy 13 (3.0) 11 (2.5) 15 (3.5)
Death 9 (2.1) 19 (4.4) 17 (3.9)
Missing assessment 18 (4.2) 24 (5.6) 22 (5.1)
Abbreviations: Arm P, placebo; Arm V, PROSTVAC; Arm VG, PROSTVAC + granulocyte-macrophage colony-stimulating factor; AWE, alive without event.
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was less robust than in postchemotherapy, likely because
of subsequent therapies.4,6 It is possible that these life-
prolonging therapies negatively affected the likelihood of
this trial achieving positive results. Despite this statistical
possibility, the lack of any signal of efficacy indicates that
PROSTVAC, as a single agent in this setting, seems to be
ineffective at a level that would justify the treatment of
unselected patients. Preclinical evidence suggested that
PROSTVAC generated fully functional T cells that were
capable of trafficking to and infiltrating into murine models
of prostate cancer.21 Accumulated immune data from
multiple National Cancer Institute clinical trials also sug-
gested that antitumor immune responses could be iden-
tified in the peripheral blood.22 The observed lack of clinical
signal suggests that either the immune responses gener-
ated in this study were not sufficient or there were other
negative regulatory influences in the tumor microenviron-
ment that prevented clinically relevant immune-mediated
killing.
GM-CSF has been adopted by cancer vaccine developers on
the basis of its properties of differentiation, migration, and
activation of dendritic cells, including an enhancement of
antigen cross-presentation23,24; however, biologic effects of
GM-CSF also stimulate other myeloid cells, includingmyeloid-
derived suppressor cells, which inhibit the functionality of
T cells.25-27 We observed an increase in adverse events in the
treatment arm that contained GM-CSF, and as a result of the
TABLE 3. Median Overall Survival by Selected Subgroups
Variable Arm V (n = 432) Arm VG (n = 432) Arm P (n = 433)
HLA-A2 status
HLA-A2 positive 200 192 183
Median OS (95% CI) 34.5 (29.4 to 41.4) 31.5 (28.0 to 38.3) 34.5 (29.0 to 39.6)
Hazard ratio (95% CI) 0.92 (0.71 to 1.20) 1.03 (0.79 to 1.35)
HLA-A2 negative 190 185 203
Median OS (95% CI) 33.9 (30.5 to 37.3) 37.2 (30.9 to 40.4) 35.5 (31.3 to 40.3)
Hazard ratio (95% CI) 1.19 (0.92 to 1.55) 1.00 (0.77 to 1.31)
Postvaccination cancer therapy
Postvaccination therapy, yes* 301 285 274
Median OS (95% CI) 37.4 (34.5 to 41.2) 38.5 (34.1 to 41.7) 37.9 (34.7 to 42.9)
Hazard ratio (95% CI) 1.06 (0.84 to 1.32) 1.09 (0.87 to 1.37)
Postvaccination therapy, no* 131 147 159
Median OS (95% CI) 20.3 (16.6 to 25.1) 23.7 (21.5 to 26.5) 23.0 (19.1 to 27.7)
Hazard ratio (95% CI) 1.10 (0.82 to 1.47) 0.95 (0.72 to 1.25)
6-Month tumor growth rate quartile†
First quartile 88 91 84
Median OS (95% CI) NA (38.2 to NA) 46.2 (38.5 to NA) 44.4 (41.3 to NA)
Hazard ratio (95% CI) 0.96 (0.59 to 1.55) 1.12 (0.70 to 1.78)
Second quartile 96 78 89
Median OS (95% CI) 36.2 (30.7 to 45.2) 49.1 (33.5 to NA) 49.6 (35.5 to NA)
Hazard ratio (95% CI) 1.26 (0.82 to 1.94) 1.03 (0.64 to 1.66)
Third quartile 92 90 81
Median OS (95% CI) 30.7 (24.9 to 35.6) 31.3 (28.3 to 34.7) 29.2 (24.9 to 35.6)
Hazard ratio (95% CI) 1.05 (0.72 to 1.51) 0.94 (0.65 to 1.37)
Forth quartile 77 87 98
Median OS (95% CI) 23.1 (18.8 to 26.6) 21.3 (17.3 to 24.6) 22.8 (19.1 to 27.2)
Hazard ratio (95% CI) 1.10 (0.78 to 1.55) 1.10 (0.79 to 1.54)
NOTE. Median OS was measured in months. Data are given as No. of patients unless otherwise noted.
Abbreviations: Arm P, placebo; Arm V, PROSTVAC; Arm VG, PROSTVAC + granulocyte-macrophage colony-stimulating factor; NA, not available; OS,
overall survival.
*Postvaccination cancer therapy with abiraterone acetate, enzalutamide, or sipuleucel-T.
†Tumor growth rates were derived for each patient with sufficient prostate-specific antigen data. More information about tumor growth rate is found in the
Data Supplement.
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overall lack of efficacy of PROSTVAC versus placebo, our data
do not support any definitive recommendation about GM-
CSF, positive or negative. Therefore, use of GM-CSF as a
vaccine adjuvant must still be considered investigational.
A correlation between growth rate constant and survival has
been reported in a retrospective analysis of five phase II
clinical trials.28 Our data are in agreement, showing a strong
correlation between slower growth rate constant and longer
TABLE 4. Best Overall Response by RECIST and Minimum Percentage Change in PSA Through Week 25/End-of-Treatment
Response Arm V (n = 432) Arm VG (n = 432) Arm P (n = 433)
Best overall response, No. (%)*
Complete 0 0 1 (0.2)
Partial 4 (0.9) 3 (0.7) 1 (0.2)
Stable disease 182 (42.1) 175 (40.5) 182 (42.0)
Progressive disease 140 (32.4) 133 (30.8) 124 (28.6)
Not evaluable 12 (2.8) 10 (2.3) 15 (3.5)
Minimum percentage change in PSA†
No. of patients 420 424 425
Mean (SD) 56.2 (685.0) 19.3 (58.4) 27.9 (79.4)
Median 18.7 13.7 20.0
Abbreviations: Arm P, placebo; Arm V, PROSTVAC; Arm VG, PROSTVAC + granulocyte-macrophage colony-stimulating factor; PSA, prostate-specific
antigen; SD, standard deviation.
*Tumor evaluation was performed using RECIST version 1.1 criteria from computed tomography or magnetic resonance imaging scans evaluated by
central reviewers for patients who completed the treatment period.
†Minimum percentage change includes the largest drop or minimum increase in PSA values during the treatment period, excluding any values post–early
termination or initiation of the next line of anticancer therapy.
TABLE 5. Adverse Events Reported as Treatment-Related in 10% of Patients or Greater
Adverse Event Preferred Term
Arm V (n = 429) Arm VG (n = 429) Arm P (n = 428)
Any Grade Grade 3-5 Any Grade Grade 3-5 Any Grade Grade 3-5
Treatment related
Any 312 (72.7) 14 (3.3)* 340 (79.3) 20 (4.7)* 302 (70.6) 11 (2.6)*
Injection site erythema 200 (46.6) 2 (0.5) 255 (59.4) 4 (0.9) 198 (46.3) 0
Injection site pain 109 (25.4) 1 (0.2) 128 (29.8) 1 (0.2) 119 (27.8) 0
Injection site pruritus 77 (17.9) 0 109 (25.4) 0 57 (13.3) 0
Injection site swelling 73 (17.0) 1 (0.2) 101 (23.5) 0 67 (15.6) 0
Fatigue 64 (14.9) 1 (0.2) 74 (17.2) 3 (0.7) 68 (15.9) 1 (0.2)
Injection site induration 46 (10.7) 1 (0.2) 67 (15.6) 0 58 (13.6) 0
Influenza-like illness 35 (8.2) 0 49 (11.4) 1 (0.2) 32 (7.5) 0
Pyrexia 28 (6.5) 0 83 (19.3) 1 (0.2) 47 (11.0) 0
Cardiac disorders, irrespective of relationship, occurring in
two or more patients in Arm V or VG
Atrial flutter 5 (1.2) 1 (0.2) 0 0 2 (0.5) 1 (0.2)
Atrial fibrillation 2 (0.5) 1 (0.2) 3 (0.7) 2 (0.5) 4 (0.9) 3 (0.7)
Bradycardia 2 (0.5) 0 0 0 0 0
Cardiac failure 2 (0.5) 2 (0.5) 1 (0.2) 1 (0.2) 0 0
Acute MI 0 0 2 (0.5) 1 (0.2) 0 0
Angina pectoris 1 (0.2) 0 2 (0.5) 0 3 (0.7) 1 (0.2)
Tachycardia 0 0 2 (0.5) 0 2 (0.5) 0
NOTE. Data are given as No. of patients (%).
Abbreviations: Arm P, placebo; Arm V, PROSTVAC; Arm VG, PROSTVAC + granulocyte-macrophage colony-stimulating factor; MI, myocardial infarction.
*No patient had any grade 4 or 5 treatment-related events, except for one patient in Arm VG who had a grade 4 event of pulmonary embolism.
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survival regardless of treatment group. Our data, however,
cannot confirm the hypothesis that patients with more indolent
mCRPC derive greater benefit from vaccine therapy than do
those with poorer prognostic factors,29 considering the absence
of anOS benefit in the entire study population. Nonetheless, we
have demonstrated that tumor growth rate, asmeasured by the
model used in this study, is a reasonable predictor of the risk of
death on a population level. This tool could be used in clinical
trials to stratify or select patients who are at high or low risk for
death, as appropriate for the primary study end point.
PROSTVAC was found to be safe and well tolerated, with no
unexpected TEAEs, which confirmed the result of earlier
studies.13,14,30 Overall, TEAEs were similar to placebo and
most commonly related to injection site reactions. An in-
creased risk for myocarditis or pericarditis has been observed
with replicating vaccinia virus strains used as preventive
vaccines for smallpox (variola).31-33 As PROSTVAC uses a
replicating vaccinia strain as the vector, cardiac adverse
events are a safety issue of special interest. No signal of
cardiotoxicity was observed in our study, even with the
population being in the high-risk category for cardiovascular
events—that is, male, older than age 65 years (approximately
75% of our population were older than age 65 years).34
Therapeutic cancer vaccines remain a valid immunother-
apy option for prostate cancer, as supported by the survival
benefit of sipuleucel-T.10 The choice of proper target an-
tigens and adjuvant components that can overcome im-
mune resistance within the tumor microenvironment are of
critical importance. Along with the confounding factors that
surround additional treatment options that became avail-
able during our study, it is not known, for instance, if the
selection of prostatic acid phosphatase in sipuleucel-T
versus PSA in PROSTVAC played a role in efficacy
evaluation.
In conclusion, we observed that vaccines induce T cells
that are capable of infiltrating tumors, but that this immune
response does not translate into clinical benefit poses a
major challenge to the immunotherapy community. His-
torical data have shown that PROSTVAC is capable of
generating specific T-cell responses against PSA as well as
cascade antigens,22 indicating that the poxvirus platform
has the potential to induce clinical benefit in the right
context—that is, with different antigen targets, in other
disease settings, and in combination with checkpoint in-
hibition. This possibility is being evaluated in ongoing
clinical trials.
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